a.nascimento
TL2 Moderator · Setúbal
Contributes reviews on supplier material. Based in Setúbal.
Joined 19 February 2025 · last posted 3h
84 posts, newest first. Showing up to 150.
-
Prescription portability between countries Replied, post #115 · Access › International · 28 Jul 2026 · 2 likes Worth separating two things that post #111 runs together. Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is…
-
Coming back to: Specificity, linearity, accuracy, precision, range, robustness — with… Replied, post #89 · Analytics › Method validation · 14 Jul 2026 · 7 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Why we ask for units every single time, with three examples of what goes wrong Replied, post #126 · Start Here › How to Ask · 13 Jul 2026 · 14 likes Five questions in one post gets you one answer: the easiest one, usually not the one you needed most. Post them separately or pick the one that depends on the others…
-
Coming back to: A newcomer's list of things that confused me, and the fixes Replied, post #9 · Start Here › Welcome · 5 Jul 2026 · 22 likes post #8 answers the question as asked. The question underneath it is different. The FAQ link in the sidebar is maintained and worth ten hours of forum browsing. It is…
-
Second pass at: Sleep apnoea improving and the equipment implications Replied, post #65 · Wellbeing › Sleep · 21 Jun 2026 · 6 likes post #64 answers the question as asked. The question underneath it is different. Obstructive sleep apnoea: pre-existing OSA can worsen with weight before it improves…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #3 · Compounds › Secretagogues & GH axis · 20 Jun 2026 · 12 likes Ipamorelin selectivity claims originate in preclinical characterisation and are reasonably well supported for what they claim: less effect on cortisol and prolactin…
-
Lipid changes during rapid weight loss: the expected trajectory Replied, post #3 · marked as the solution · Clinical › Bloodwork · 6 Jun 2026 · 11 likes Lipid panel interpretation: total, LDL, HDL, triglycerides all on one panel. Reading them together is more informative than reading one value in isolation. An elevated…
-
The most useful thing you learned here that was not the answer you came for Replied, post #44 · Lounge › Off topic · 22 May 2026 · 2 likes Politics and public policy: healthcare policy that affects access to these compounds is relevant here. Partisan politics is not.
-
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #78 · Outcomes › Body composition · 18 May 2026 · 10 likes Changes during titration: measuring body composition during active titration is less useful than measuring after dose is stable. Titration causes fluid shifts that…
-
[2026 update] Waist circumference technique and its repeatability Replied, post #10 · Outcomes › Progress reports · 17 May 2026 · 0 likes Plateaus and resets: if weight loss stalls and then resumes, that is ordinary. It is not evidence that the medication stopped working. It is not evidence that it is…
-
Amylin receptor signalling and satiety — what changed since Replied, post #74 · Pharmacology › Receptor biology · 5 May 2026 · 22 likes Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ…
-
Run-in periods and the population they select Replied, post #109 · Evidence › Trials · 1 May 2026 · 0 likes Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why…
-
Revisiting: PCOS and metabolic overlap: what is and is not studied Replied, post #21 · Clinical › Comorbidities · 27 Apr 2026 · 0 likes Bariatric surgery history: altered anatomy after surgery affects absorption. That matters for oral medications and for reconstituted solutions. Discussing specific…
-
[2026 update] Charge states for a 4 kDa peptide, worked through Replied, post #115 · Analytics › Mass spectrometry · 26 Apr 2026 · 9 likes Sample matrix effects: if a sample is dissolved in a complex matrix, other compounds in the matrix can suppress the peptide signal. Clean samples give higher…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #24 · Practice › Reconstitution · 25 Apr 2026 · 0 likes The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL is the most common arithmetic error in this subcategory. The habit that catches it:…
-
The best-written scientific paper you have read Replied, post #17 · Lounge › Off topic · 24 Apr 2026 · 3 likes This follows post #14 rather than contradicting it. Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have…
-
Converting between mg/mL and units per dose, both directions — the long version Replied, post #93 · Practice › Reconstitution · 24 Apr 2026 · 6 likes Osmolarity and reconstitution: the osmolarity of the reconstituted solution affects comfort on injection. Isotonic solutions (close to blood osmolarity) are less…
-
Converting between mg/mL and units per dose, both directions — the long version Replied, post #78 · Practice › Reconstitution · 23 Apr 2026 · 0 likes Reconstituting a multi-strength kit: if a kit contains 5 mg, 10 mg, 15 mg vials and you are reconstituting all of them, writing the concentration on each vial in…
-
Converting between mg/mL and units per dose, both directions — the long version Replied, post #10 · Practice › Reconstitution · 17 Apr 2026 · 27 likes Choosing a concentration on purpose rather than by accident: starting with "I want to draw 0.5 mL per dose" and working backward to the required concentration is more…
-
Spike-and-recover accuracy for a peptide assay Replied, post #97 · Analytics › Method validation · 10 Apr 2026 · 18 likes Transfer between laboratories: a method can be transferred from one lab to another, but the receiving lab needs to demonstrate that they can achieve the same…
-
Adducts: sodium, potassium, and the peak you did not expect — does this still hold? Replied, post #101 · Analytics › Mass spectrometry · 9 Apr 2026 · 29 likes Electrospray ionisation produces multiply charged ions. For a 4 kDa peptide you expect mostly 2+, 3+, and 4+ charge states. Reading an electrospray spectrum means…
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #36 · Sourcing › Independent verification · 2 Apr 2026 · 12 likes I read post #34 twice before replying, because I had assumed the opposite. VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than…
-
[2026 update] Thyroid function tests during substantial weight change Replied, post #17 · Clinical › Bloodwork · 18 Mar 2026 · 0 likes This follows post #14 rather than contradicting it. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still…
-
A site rotation scheme that is easy enough to actually follow Replied, post #17 · Practice › Administration · 9 Mar 2026 · 0 likes Cold solution and stinging: warming the vial in your hands for a minute before injection reduces the stinging sensation substantially. This is the simplest thing to try…
-
Why a compound being unapproved is not the same as being illegal to possess Replied, post #62 · Sourcing › Regulatory · 24 Feb 2026 · 0 likes Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is…
-
Second pass at: Where impurities in solid-phase peptide synthesis come from Replied, post #22 · Analytics › Impurities & related substances · 22 Feb 2026 · 23 likes Coming back to post #20, because the follow-up matters more than the original answer. Aggregates: multiples of the monomer mass. May not elute at all under a standard…
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #2 · Practice › Interactions · 20 Feb 2026 · 0 likes the opening post answers the question as asked. The question underneath it is different. Thyroid medications: semaglutide is associated with a slowing of gastric…
-
Trifluoroacetate content and its consequences Replied, post #20 · Analytics › Impurities & related substances · 25 Jan 2026 · 0 likes Dimer and higher-order multimers: two or more peptide molecules bonded together. They appear at double the mass and higher. They may or may not separate from the…
-
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #50 · Sourcing › Red flags · 14 Jan 2026 · 28 likes post #49 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather…
-
Coming back to: Training through a dose escalation week Replied, post #7 · Nutrition & Training › Resistance training · 12 Jan 2026 · 0 likes Recovery: heavier training on a energy deficit and on a compound that slows gastric emptying requires attention to recovery (sleep, nutrition, stress). Recovery…
-
Search filters: what is missing Replied, post #14 · Meta › Site feedback · 1 Jan 2026 · 0 likes Navigation problems: if you cannot find something you expected to exist, or the path to it is unclear, report it. Site architecture affects usability.
-
Aggregates and why a purity assay may miss them entirely Replied, post #40 · Analytics › Impurities & related substances · 31 Dec 2025 · 0 likes Coming back to post #38, because the follow-up matters more than the original answer. Acetate content: counter-ion content. Trifluoroacetate or acetate from the salt…
-
Vomiting: when it is expected and when it is a reason to stop Replied, post #80 · Practice › Side effects · 29 Dec 2025 · 1 like Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not specific to this drug class. The risk is greatest in the…
-
Can a home kit substitute for a laboratory report? A careful no Replied, post #82 · Analytics › Home & field testing · 18 Dec 2025 · 2 likes What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline alone), rough screening for very different compounds…
-
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #37 · Access › Pricing · 14 Dec 2025 · 0 likes Pharmacy acquisition cost: a pharmacy pays less than the patient pays, even at insurance rates. That margin is where the pharmacy's costs and profit live.
-
Promotion criteria, and the one that stops most nominations — the long version Replied, post #112 · Documentation › Doc review · 14 Dec 2025 · 1 like Revision disputes: if you disagree with an edit a maintainer made to a page, discuss it here. The goal is accuracy and clarity, not authorship.
-
Publishing an inconvenient result: a case study — the long version Replied, post #64 · Sourcing › Independent verification · 9 Dec 2025 · 0 likes Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and…
-
Packaging that arrived damaged: documenting it properly — a second dataset Replied, post #5 · Sourcing › Logistics · 7 Dec 2025 · 29 likes Cold packs and temperature control: inclusion of cold packs at despatch is standard. Whether they maintain temperature through transit depends on journey duration and…
-
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #6 · Compounds › Tirzepatide · 29 Nov 2025 · 23 likes Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted…
-
Sequence verification for an obscure compound: how it is done — what changed since Replied, post #26 · Compounds › Other compounds · 23 Nov 2025 · 23 likes Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds…
-
Moderation log format change Replied, post #9 · Meta › Announcements · 18 Nov 2025 · 19 likes When announcements are made: major policy changes, technical changes affecting site function, planned downtime, and changes to guidelines all get announced here.
-
The anatomy of a question that gets answered within an hour — the long version Replied, post #110 · Start Here › How to Ask · 18 Nov 2025 · 1 like Worth separating two things that post #106 runs together. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather…
-
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #10 · Analytics › Impurities & related substances · 14 Nov 2025 · 0 likes Aggregates: multiples of the monomer mass. May not elute at all under a standard reversed-phase method. A species that does not come off the column does not appear in…
-
Promotion criteria, and the one that stops most nominations — the long version Replied, post #75 · Documentation › Doc review · 15 Oct 2025 · 0 likes Revision disputes: if you disagree with an edit a maintainer made to a page, discuss it here. The goal is accuracy and clarity, not authorship.
-
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #45 · Compounds › Oral incretins · 3 Oct 2025 · 20 likes Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of…
-
Why the timeline is on the right and not the left Replied, post #68 · Meta › Site feedback · 14 Sep 2025 · 0 likes Display issues: broken layouts, images not loading, text overlapping — report with the browser and device you were using. Display bugs are platform-specific.
-
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #3 · Evidence › Study critique · 12 Sep 2025 · 4 likes Confounding: in observational data, is there a third variable that explains the apparent association? In randomised data, randomisation should balance unknown…
-
Reaching a dose and staying there for a year: a longitudinal note — does this still hold? Replied, post #38 · Practice › Dosing & titration · 7 Sep 2025 · 0 likes post #37 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than…
-
A parcel that arrived warm: a decision process, not a verdict Replied, post #28 · Practice › Storage & stability · 7 Sep 2025 · 7 likes This follows post #25 rather than contradicting it. Dating prepared solutions: write the date reconstitution on the vial in permanent marker. If you later need to know…
-
Meeting a protein target on a suppressed appetite Replied, post #19 · Nutrition & Training › Protein & intake · 2 Sep 2025 · 0 likes Protein targets during weight loss: the standard recommendation is 1.6 to 2.2 grams per kilogram of body weight. Individual requirements vary but that range is a…
-
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #92 · Compounds › Cagrilintide & amylin analogues · 2 Sep 2025 · 10 likes Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and…
-
Second pass at: The mass-error checker and its intended scope Replied, post #9 · Data & Tools › Calculators · 31 Aug 2025 · 0 likes The calculators maintained on this site are open-source and verifiable. They are intended to check arithmetic, not to replace medical judgement. Using them is optional…
-
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #96 · Data & Tools › Calculators · 27 Aug 2025 · 3 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
A request that was declined, and the reasoning — a second dataset Replied, post #23 · Documentation › Wiki requests · 7 Aug 2025 · 1 like I read post #21 twice before replying, because I had assumed the opposite. Suggesting content for a page: if you know a maintained page is missing something important,…
-
Coming back to: Official shortage notices and what they authorise Replied, post #65 · Access › Shortages · 22 Jul 2025 · 7 likes Worth separating two things that post #61 runs together. Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply…
-
Publishing an inconvenient result: a case study Replied, post #41 · Sourcing › Independent verification · 29 Jun 2025 · 5 likes Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not…
-
[2026 update] Cardiovascular risk: reading the outcome trials as a set Replied, post #60 · Clinical › Comorbidities · 27 Jun 2025 · 2 likes This follows post #57 rather than contradicting it. Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed resolution was more frequent…
-
Why oral semaglutide needs an absorption enhancer at all Replied, post #14 · Compounds › Oral incretins · 25 Jun 2025 · 0 likes I read post #12 twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write…
-
Hepatic steatosis: what the MASH trial evidence supports Replied, post #59 · Clinical › Comorbidities · 7 Jun 2025 · 0 likes Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents,…
-
A report I filed that turned out to be wrong, and the correction Replied, post #87 · Sourcing › Vendor reports · 5 Jun 2025 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #77 · Practice › Reconstitution · 25 May 2025 · 0 likes Arithmetic step by step: a 5 mg vial with 2 mL of diluent gives (5 mg) / (2 mL) = 2.5 mg/mL. On a U-100 syringe at that concentration, 100 units = 1 mL = 2.5 mg, so…
-
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ Replied, post #13 · Sourcing › Independent verification · 25 Apr 2025 · 2 likes Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is…
-
Preparing for an appointment: one page, three questions Replied, post #15 · Clinical › Prescriber conversations · 18 Apr 2025 · 12 likes How to ask for what you need: rather than "should I take this", frame it as "I understand the evidence for this shows X benefit in people with my condition; would it be…
-
Carryover and the ghost peak from last week's standard Replied, post #11 · Analytics › HPLC & UHPLC · 2 Apr 2025 · 24 likes System suitability testing: injections run before and during the sample run to establish whether the instrument, column and method were performing when the sample was…
-
Coming back to: What published stability data actually covers, and what it does not Replied, post #13 · Practice › Storage & stability · 30 Mar 2025 · 3 likes post #12 is right about the mechanism and I think understates the practical bit. Container choice matters: the material of the vial, the rubber closure, the fill volume…
-
Retatrutide dose escalation in the published trials Replied, post #63 · Compounds › Retatrutide · 29 Mar 2025 · 23 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
-
Coverage for the indication versus for the drug Replied, post #8 · Access › Insurance & coverage · 23 Mar 2025 · 0 likes post #7 answers the question as asked. The question underneath it is different. Denial letters: the stated reason tells you exactly what to submit next. A denial is not…
-
Why cagrilintide alone is discussed so much less than in combination Replied, post #8 · Compounds › Cagrilintide & amylin analogues · 22 Mar 2025 · 15 likes For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not…
-
Pharmaceutical compounding rules, summarised from primary sources Replied, post #93 · Sourcing › Regulatory · 3 Mar 2025 · 9 likes post #92 is right about the mechanism and I think understates the practical bit. Off-label use and medical practice: clinicians can prescribe approved medications…
-
Follow-up: Individual participant data versus aggregate data Replied, post #73 · Evidence › Meta-analyses · 10 Jan 2025 · 3 likes Fixed-effects versus random-effects models: fixed-effects assumes all studies are estimating the same thing and variation is sampling error. Random-effects assumes…
-
When "no data" is the complete and final answer Replied, post #58 · Compounds › Other compounds · 5 Jan 2025 · 21 likes Picking up post #55: that is the part I would want checked first. Naming conventions for research peptides cause confusion because suppliers do not follow a standard.…
-
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #102 · Compounds › Oral incretins · 28 Dec 2024 · 12 likes I read post #100 twice before replying, because I had assumed the opposite. SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that…
-
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #10 · Compounds › Semaglutide · 16 Dec 2024 · 7 likes Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and…
-
[2026 update] New subcategory: rationale and scope Replied, post #68 · Meta › Announcements · 15 Dec 2024 · 25 likes post #67 answers the question as asked. The question underneath it is different. Notifications: watching this subcategory means you receive notifications when…
-
Injection-site reactions: describing them precisely enough to be useful Replied, post #50 · Practice › Side effects · 6 Dec 2024 · 5 likes This follows post #47 rather than contradicting it. Injection site reaction: local erythema, nodules, or induration at injection sites is reported by some people. Site…
-
Tracking semaglutide's approved indications across jurisdictions, dated — does this… Replied, post #52 · Compounds › Semaglutide · 30 Nov 2024 · 0 likes The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no…
-
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #141 · Compounds › Repair & healing peptides · 25 Nov 2024 · 4 likes For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or…
-
How to ask for a dose change without antagonising anyone — what changed since Replied, post #93 · Clinical › Prescriber conversations · 23 Nov 2024 · 6 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
-
When to suspect the method rather than the sample Replied, post #16 · Analytics › Method validation · 25 Sep 2024 · 12 likes This follows post #13 rather than contradicting it. Why two laboratories may disagree: after validating the same method, they may still report different purity on the…
-
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #81 · Sourcing › Independent verification · 24 Sep 2024 · 0 likes post #80 answers the question as asked. The question underneath it is different. How to submit a sample: contact the service directly. They will provide instructions on…
-
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #4 · Compounds › Other compounds · 15 Sep 2024 · 24 likes Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have…
-
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #9 · Compounds › Semaglutide · 11 Sep 2024 · 1 like The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice.…
-
The topic list is dense — is that deliberate? Replied, post #18 · Meta › Site feedback · 26 Aug 2024 · 11 likes Search and findability: if you searched for something and did not find it, report what you searched for and what you expected to find. That helps improve indexing and…
-
Guidelines revision: what changed and why Replied, post #13 · Meta › Announcements · 25 Jul 2024 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.